Literature DB >> 27390279

Eosinophilic pneumonia associated with pirfenidone therapy.

Diana C Gomez1, Borna Mehrad2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27390279      PMCID: PMC5575853          DOI: 10.1183/13993003.00809-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  8 in total

1.  Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?

Authors:  S Campainha; C Nogueira; F Costa; A Sanches; S Neves
Journal:  Rev Port Pneumol (2006)       Date:  2015-11-21

Review 2.  Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia.

Authors:  Joshua Solomon; Marvin Schwarz
Journal:  Semin Respir Crit Care Med       Date:  2006-04       Impact factor: 3.119

Review 3.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

4.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.

Authors:  Ganesh Raghu; Bram Rochwerg; Yuan Zhang; Carlos A Cuello Garcia; Arata Azuma; Juergen Behr; Jan L Brozek; Harold R Collard; William Cunningham; Sakae Homma; Takeshi Johkoh; Fernando J Martinez; Jeffrey Myers; Shandra L Protzko; Luca Richeldi; David Rind; Moisés Selman; Arthur Theodore; Athol U Wells; Henk Hoogsteden; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

5.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

6.  Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  J S Lee; J W Song; P J Wolters; B M Elicker; T E King; D S Kim; H R Collard
Journal:  Eur Respir J       Date:  2011-12-19       Impact factor: 16.671

7.  [A case of drug-induced pneumonia possibly associated with simvastatin].

Authors:  Sumako Yoshioka; Hiroshi Mukae; Hiroshi Ishii; Seiko Nakayama; Keiko Hisatomi; Hiroshi Ishimoto; Tomoyuki Kakugawa; Kanako Sugiyama; Mioko Ide; Shigeru Kohno
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2005-10

Review 8.  Drug-induced eosinophilic lung disease.

Authors:  James N Allen
Journal:  Clin Chest Med       Date:  2004-03       Impact factor: 2.878

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.